{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:06:46Z","timestamp":1747181206279,"version":"3.40.5"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Multiple myeloma (MM) is a malignant plasma cell disease. In recent years, several systematic reviews, and meta-analyses have been published on treatment protocols, including autologous stem cell transplantation for MM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Web of Science, PubMed, Embase, and Cochrane Library were searched to systematically summarize the quality of the methodology and evidence of meta-analyses regarding treatment of MM including autologous stem cell transplantation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Total 11 meta-analyses were included. The preferred reporting items for systematic reviews and meta-analyses evaluation revealed that the quality of included reviews was affected by possible unevaluated bias between studies and the lack of protocol and registration. The AMSTAR2 scale indicated that the quality of the methodology of included reviews ranged from very low to moderate. The grading, assessment, development, and evaluation of recommendations evaluation showed that among the included outcome indicators, most of them are of low quality.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This overview suggested that the combination of drugs has improved patient survival rates, efficacy and safety compared with the standard regimen. However, the strength of the evidence is uneven and due to methodological errors, the results should be interpreted with caution in order to provide a reference for further improvement of the study design. The methodological quality of the relevant meta-analysis needs to be further improved.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000035456","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T12:03:58Z","timestamp":1696593838000},"page":"e35456","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of multiple myeloma based on autologous stem cell transplant: An overview of systematic reviews"],"prefix":"10.1097","volume":"102","author":[{"given":"Juan","family":"Liang","sequence":"first","affiliation":[{"name":"School of Public Health, Zhejiang Chinese Medical University, Hangzhou, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peijie","family":"He","sequence":"additional","affiliation":[{"name":"School of Public Health, Zhejiang Chinese Medical University, Hangzhou, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar Onayi","family":"Mandizadza","sequence":"additional","affiliation":[{"name":"School of Public Health, Zhejiang Chinese Medical University, Hangzhou, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanjun","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengyun","family":"Lin","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8329-8927","authenticated-orcid":false,"given":"Conghua","family":"Ji","sequence":"additional","affiliation":[{"name":"School of Public Health, Zhejiang Chinese Medical University, Hangzhou, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"188","DOI":"10.7861\/clinmedicine.19-2-188a","article-title":"Haematology: multiple myeloma.","volume":"19","author":"Cullis","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy.","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5694\/mja2.50129","article-title":"Biology and therapy of multiple myeloma.","volume":"210","author":"Joshua","year":"2019","journal-title":"Med J Aust"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma.","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/pds.3927","article-title":"Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model.","volume":"25","author":"Cid Ruzafa","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2141.2004.05207.x","article-title":"A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK.","volume":"127","author":"Phekoo","year":"2004","journal-title":"Br J Haematol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1001\/archinte.1996.00440120125014","article-title":"Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature.","volume":"156","author":"Blad\u00e9","year":"1996","journal-title":"Arch Intern Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016.","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/cas.12594","article-title":"Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug\/proteasome inhibitor era.","volume":"106","author":"Takamatsu","year":"2015","journal-title":"Cancer Sci"},{"issue":"suppl_4","key":"R12-20250504","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"28","author":"Morea","year":"2017","journal-title":"Ann Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"101929","DOI":"10.1016\/j.ctrv.2019.101929","article-title":"Multiple myeloma: role of autologous transplantation.","volume":"82","author":"Ntanasis-Stathopoulos","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/2040620718761776","article-title":"The evolution of stem-cell transplantation in multiple myeloma.","volume":"9","author":"Mahajan","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2017-0328","article-title":"EMA review of daratumumab for the treatment of adult patients with multiple myeloma.","volume":"23","author":"Tzogani","year":"2018","journal-title":"Oncologist"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2010.313","article-title":"Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and\/or transplant ineligible patients with multiple myeloma: a meta-analysis.","volume":"25","author":"Kapoor","year":"2011","journal-title":"Leukemia"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jrsm.30","article-title":"The evolution of a new publication type: steps and challenges of producing overviews of reviews.","volume":"1","author":"Thomson","year":"2010","journal-title":"Res Synth Methods"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jebm.12141","article-title":"The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review.","volume":"8","author":"Zeng","year":"2015","journal-title":"J Evid Based Med"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1398-9995.2009.01973.x","article-title":"Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions.","volume":"64","author":"Brozek","year":"2009","journal-title":"Allergy"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/jrsm.1535","article-title":"Introduction to PRISMA 2020 and implications for research synthesis methodologists.","volume":"13","author":"Page","year":"2021","journal-title":"Res Synth Methods"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both.","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"e8109","DOI":"10.5867\/medwave.2021.02.8109","article-title":"The GRADE approach, Part 1: how to assess the certainty of the evidence.","volume":"21","author":"Kirmayr","year":"2021","journal-title":"Medwave"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1007\/s12325-022-02195-1","article-title":"Triplet RVd induction for transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis.","volume":"39","author":"Yang","year":"2022","journal-title":"Adv Ther"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","article-title":"Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis.","volume":"4","author":"Dhakal","year":"2018","journal-title":"JAMA Oncol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/ejh.12961","article-title":"Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: a systematic review.","volume":"99","author":"Al-Ani","year":"2017","journal-title":"Eur J Haematol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","article-title":"Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: a systematic review and meta-analysis.","volume":"67","author":"Teh","year":"2016","journal-title":"Eur J Cancer"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjh.12946","article-title":"Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.","volume":"166","author":"Leiba","year":"2014","journal-title":"Br J Haematol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.3109\/10428194.2013.774393","article-title":"Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma.","volume":"54","author":"Zou","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/CAD.0b013e32836032d5","article-title":"Continuous treatment with new agents for newly diagnosed multiple myeloma.","volume":"24","author":"Zou","year":"2013","journal-title":"Anticancer Drugs"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgo.2019.05.014","article-title":"Autologous stem cell transplant in older patients (age \u2265 65) with newly diagnosed multiple myeloma: a systematic review and meta-analysis.","volume":"11","author":"Mian","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bbmt.2018.09.021","article-title":"High-dose chemotherapy with early autologous stem cell transplantation compared to standard dose chemotherapy or delayed transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis.","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/djn439","article-title":"Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.","volume":"101","author":"Kumar","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbmt.2006.09.010","article-title":"High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.","volume":"13","author":"Koreth","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4103\/0019-5154.127671","article-title":"Understanding and evaluating systematic reviews and meta-analyses.","volume":"59","author":"Bigby","year":"2014","journal-title":"Indian J Dermatol"},{"key":"R39-20250504","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.3390\/cancers12102885","article-title":"Multiple myeloma: an overview of the current and novel therapeutic approaches in 2020.","volume":"12","author":"Bobin","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:06:51Z","timestamp":1746328011000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":40,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035456","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2023,10,6]]}}}